NEW DELHI: "Ranbaxy has always been at the forefront in addressing the healthcare needs by providing cost-effective and quality medicines," said Brian Tempest, president (pharmaceuticals) of Ranbaxy Laboratories Limited. "To address the growing menace of HIV around the world, Ranbaxy will pledge to serve a large part of the global demand of anti-retrovirals," he added. Ranbaxy's has filed 300 registrations in 54 countries during the last 18 months for selling anti-AIDS drugs, said a company statement, adding the company has gained recognition as a major player by developing a range of generic anti-retrovirals. New Delhi-based Ranbaxy markets its anti-AIDS range of products in several countries that include developing nations like Burkina Faso, Myanmar, Nigeria, Vietnam and Zambia. Ranbaxy's subsidiary in South Africa and Tiger Brands Healthcare division, Adcock Ingram, formed a joint venture last month to exclusively sell and distribute Ranbaxy's range of anti-retroviral products in South Africa. In the Indian market, the company has one of the largest ranges of bio-equivalent generic anti-retrovirals such as Lamivudine, Stavudine, Zidovudine, Indinavir, Nevirapine and Efavirenz. Ranbaxy sells its products in over 100 countries and has marketing operations in 25 countries and manufacturing operations in 7 countries.
Source: IANS